Journal of Medicinal Chemistry · 2021 · 37 citations · 11 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationMolecular PharmacologyLigand-based DesignPotency OptimizationC-jun N-terminal Kinase SignalingIn Vivo Efficacy TestingIn Vivo StudiesJnk Signaling PathwayKinase Inhibitor Library DesignKinase InhibitorsProtein Kinase InhibitorsSystemic Exposure Assessment
As a result of emerging biological data suggesting that within the c-Jun N-terminal kinase (JNK) family, JNK1 and not JNK2 or JNK3 may be primarily responsible for fibrosis pathology, we sought to identify JNK inhibitors with an increased JNK1 bias relative to our previous clinical compound tanzisertib (CC-930). This manuscript reports the synthesis and structure–activity relationship (SAR) studies for a novel series of JNK inhibitors demonstrating an increased JNK1 bias. SAR optimization on a series of 2,4-dialkylamino-pyrimidine-5-carboxamides resulted in the identification of compounds possessing low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. Optimization of physicochemical properties in this series resulted in compounds that demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of a candidate for clinical development, CC-90001, which is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).
11
Requirement of JNK for Stress- Induced Activation of the Cytochrome c-Mediated Death Pathway
Cathy Tournier, Patricia Hess, Derek Yang et al. · Science · 2000 · 1.7K citations
Raed Lattouf, Ronald Younes, Didier Lutomski et al. · Journal of Histochemistry & Cytochemistry · 2014 · 504 citations · Full text
Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance†
Rajat Singh, Yongjun Wang, Youqing Xiang et al. · Hepatology · 2008 · 219 citations · Full text